Genprex Inc. (NASDAQ: GNPX) Raising the Bar in Cancer Therapeutics

Several revolutionary gene therapies appear to be on the verge of delivering remarkable remedies for diseases that have previously been viewed as untreatable.

• Gene therapy is the next great leap forward in medicine, with several noteworthy programs underway looking to cure the incurable
• FDA expects 200 new gene and cell therapy INDs in next two years
• Genprex — and its initial product candidate Oncoprex — is pioneering a new approach to treating cancer.

Built on decades of scientific research and innovation, gene therapy is the next frontier of medicine, determined to provide remedies for previously untreatable diseases and unmet medical needs. At the forefront of this gene therapy revolution, Genprex Inc. (NASDAQ: GNPX) is pioneering a new paradigm in cancer therapeutics. The company’s first target is non-small cell lung cancer, and research indicates that Genprex’s novel technology might also deliver other cancer-fighting genes to combat a variety of different cancers. Sangamo Therapeutics Inc. (NASDAQ: SGMO) is conducting landmark studies to treat hemophilia, inherited metabolic disorders and other serious diseases at the genomic level. uniQure N.V. (NASDAQ: QURE) is leveraging its technology platform to advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and other severe genetic diseases. bluebird bio Inc. (NASDAQ: BLUE) is developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies. And Leap Therapeutics Inc. (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics.